The prognostic value of pretreatment albumin-to-fibrinogen ratio in small cell lung cancer patients receiving first-line platinum-based chemotherapy

被引：3
|
作者：
Li, Qi [1 ]
Li, Li [1 ]
Wang, Yuchao [1 ]
Xu, Chunhua [1 ,4 ]
Zou, Jue [2 ,3 ]
机构：
[1] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Resp Med, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Resp Med, 215 Guangzhou Rd, Nanjing 210029, Peoples R China
[4] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Pathol, 215 Guangzhou Rd, Nanjing 210029, Peoples R China
来源：
HELIYON | 2023年 / 9卷 / 09期
关键词：
SCLC; Chemotherapy; Prognosis; AFR; INFLAMMATION;
D O I：
10.1016/j.heliyon.2023.e19225
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
This study examined the role of pretreatment albumin-to-fibrinogen ratio (AFR) in the prognosis of small-cell lung cancer (SCLC) patients receiving first-line platinum-based chemotherapy. A total of 131 SCLC patients were enrolled. The predictive value of the AFR for progression free survival (PFS) and overall survival (OS) were evaluated by receiver operating characteristic (ROC) curve analysis. The predictive factor of survival was assessed by univariate and multivariate Cox proportional regression analysis. The correlation between OS, PFS and AFR was determined by the log-rank test using the Kaplan-Meier method. AFR was an effective predictor of OS in SCLC patients with a cut-off value of 7.78. AFR was independent risk factors for OS and PFS. Kaplan Meier analysis showed that PFS and OS in patients with high AFR levels were significantly higher than those with low AFR levels. These results suggest that AFR could be an effective predictor of survival in patients with SCLC.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients
    Song, Ying-Jian
    Wang, Li-Xin
    Hong, Yong-Qing
    Lu, Zheng-Hong
    Tong, Qiang
    Fang, Xiao-Zheng
    Tan, Juan
    TUMOR BIOLOGY, 2016, 37 (04) : 5285 - 5293
  • [22] Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival
    Sirohi, Bhawna
    Ashley, Sue
    Norton, Alison
    Popat, Sanjay
    Hughes, Sarah
    Papadopoulos, Panagiotous
    Priest, Kathryn
    O'Brien, Mary
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 735 - 740
  • [23] Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Rizvi, Naiyer A.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Gettinger, Scott
    Chow, Laura Q.
    Gerber, David E.
    Laurie, Scott A.
    Goldman, Jonathan W.
    Shepherd, Frances A.
    Chen, Allen C.
    Shen, Yun
    Nathan, Faith E.
    Harbison, Christopher T.
    Antonia, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2969 - +
  • [24] Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
    Evans, Tracey L.
    Cho, Byoung Chul
    Udud, Katalin
    Fischer, Juergen R.
    Shepherd, Frances A.
    Martinez, Pablo
    Ramlau, Rodryg
    Syrigos, Konstantinos N.
    Shen, Liji
    Chadjaa, Mustapha
    Wolf, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) : 1221 - 1228
  • [25] Clinical outcomes for advanced thymoma patients receiving platinum-based chemotherapy as first-line treatment
    Hao, Y.
    Sun, W.
    Zeng, X.
    Shi, Z.
    Wang, W.
    Xu, C.
    Song, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S157 - S157
  • [26] Survival by Response to First-line Platinum-Based Therapy Among Patients With Extensive Disease Small Cell Lung Cancer
    Danese, M.
    Gleeson, M.
    Lubeck, D.
    Penrod, J.
    Korytowsky, B.
    Yuan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2043 - S2043
  • [27] Editorial on "Albumin-to-fibrinogen ratio as a prognostic biomarker to predict clinical outcome of non-small cell lung cancer individuals"
    Miyazaki, Takuro
    Nagayasu, Takeshi
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1241 - S1244
  • [28] RANDOMIZED PHASE II STUDY OF BELOTECAN OR TOPOTECAN CHEMOTHERAPY AS SECOND-LINE CHEMOTHERAPY AFTER PLATINUM-BASED FIRST-LINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER
    Yoon, S.
    Lee, D. H.
    Choi, C.
    Lee, J. C.
    Lee, J. S.
    Kim, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
    Tao, Kai-Yi
    Li, Xian-Xing
    Xu, Wei-Zhen
    Wang, Yin
    Zhu, Shuang-Mei
    Xie, Hua-Xia
    Luo, Wen-Hua
    Xu, Yan-Jun
    Xu, Xiao-Ling
    ONCOTARGETS AND THERAPY, 2015, 8 : 147 - 155
  • [30] Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy
    Claps, Francesco
    Rai, Samarpit
    Mir, Maria Carmen
    van Rhijn, Bas W. G.
    Mazzon, Giorgio
    Davis, Laura Elizabeth
    Valadon, Crystal Lynn
    Silvestri, Tommaso
    Rizzo, Michele
    Ankem, Murali
    Liguori, Giovanni
    Celia, Antonio
    Trombetta, Carlo
    Pavan, Nicola
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (12) : 835.e9 - 835.e17
12345